N Feltelius

Summary

Affiliation: Medical Products Agency
Country: Sweden

Publications

  1. ncbi request reprint [New drugs require nw follow-up surveillance]
    N Feltelius
    Institutionen för medicin, Karolinska sjukhuset Karolinska institutet, Stockholm
    Lakartidningen 98:951-3. 2001
  2. pmc Cancer incidence among patients with ankylosing spondylitis in Sweden 1965-95: a population based cohort study
    N Feltelius
    Unit of Rheumatology, Department of Medicine at Karolinska Hospital, Karolinska Institutet, Stockholm, Sweden
    Ann Rheum Dis 62:1185-8. 2003
  3. pmc Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept
    N Feltelius
    Swedish Medical Products Agency, PO Box 26, SE 751 03 Uppsala, Sweden
    Ann Rheum Dis 64:246-52. 2005
  4. doi request reprint Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register
    J Askling
    Department of Medicine, Clinical Epidemiology Unit, Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden
    Ann Rheum Dis 68:648-53. 2009
  5. doi request reprint Sick leave and disability pension before and after initiation of antirheumatic therapies in clinical practice
    M Neovius
    Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
    Ann Rheum Dis 70:1407-14. 2011
  6. pmc Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists
    J Askling
    Clinical Epidemiology Unit, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden
    Ann Rheum Dis 64:1414-20. 2005
  7. doi request reprint Generalisability of clinical registers used for drug safety and comparative effectiveness research: coverage of the Swedish Biologics Register
    M Neovius
    Department of Medicine, Karolinska Institutet, SE 171 76 Stockholm, Sweden
    Ann Rheum Dis 70:516-9. 2011
  8. doi request reprint How large are the productivity losses in contemporary patients with RA, and how soon in relation to diagnosis do they develop?
    Martin Neovius
    Clinical Epidemiology Unit T2, Department of Medicine Solna, Karolinska Institutet, SE 171 76 Stockholm, Sweden
    Ann Rheum Dis 70:1010-5. 2011
  9. ncbi request reprint Rheumatoid arthritis in Sweden. Drug prescriptions, costs, and adverse drug reactions
    P Blomqvist
    Karolinska Institutet, Department of Medical Epidemiology, Stockholm, Sweden
    J Rheumatol 27:1171-7. 2000
  10. doi request reprint Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden
    Martin Neovius
    Clinical Epidemiology Unit T2, Department of Medicine Solna, Karolinska Institutet, SE 171 76 Stockholm, Sweden
    Ann Rheum Dis 70:624-9. 2011

Detail Information

Publications16

  1. ncbi request reprint [New drugs require nw follow-up surveillance]
    N Feltelius
    Institutionen för medicin, Karolinska sjukhuset Karolinska institutet, Stockholm
    Lakartidningen 98:951-3. 2001
    ..This was implemented already in the pre-marketing phase, and is presently being continued as an observational study after approval. Experience from the development phase of this system and some preliminary results are presented...
  2. pmc Cancer incidence among patients with ankylosing spondylitis in Sweden 1965-95: a population based cohort study
    N Feltelius
    Unit of Rheumatology, Department of Medicine at Karolinska Hospital, Karolinska Institutet, Stockholm, Sweden
    Ann Rheum Dis 62:1185-8. 2003
    ..The disease associated cancer risk has been poorly explored. Recently, tumour necrosis factor alpha blockers have been found to be efficacious in AS, but their long term risk is unknown...
  3. pmc Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept
    N Feltelius
    Swedish Medical Products Agency, PO Box 26, SE 751 03 Uppsala, Sweden
    Ann Rheum Dis 64:246-52. 2005
    ..To describe a nationwide system for postmarketing follow up of new antirheumatic drugs in Sweden, and to analyse safety and effectiveness in an etanercept treated patient cohort...
  4. doi request reprint Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register
    J Askling
    Department of Medicine, Clinical Epidemiology Unit, Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden
    Ann Rheum Dis 68:648-53. 2009
    ....
  5. doi request reprint Sick leave and disability pension before and after initiation of antirheumatic therapies in clinical practice
    M Neovius
    Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
    Ann Rheum Dis 70:1407-14. 2011
    ..To investigate sick leave and disability pension in rheumatoid arthritis (RA) in relation to the initiation of biological and non-biological antirheumatic therapies in clinical practice...
  6. pmc Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists
    J Askling
    Clinical Epidemiology Unit, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden
    Ann Rheum Dis 64:1414-20. 2005
    ..Patients with rheumatoid arthritis (RA) are at increased risk of malignant lymphomas, and maybe also of leukaemia and multiple myeloma. The effect of tumour necrosis factor (TNF) antagonists on lymphoma risk and characteristics is unclear...
  7. doi request reprint Generalisability of clinical registers used for drug safety and comparative effectiveness research: coverage of the Swedish Biologics Register
    M Neovius
    Department of Medicine, Karolinska Institutet, SE 171 76 Stockholm, Sweden
    Ann Rheum Dis 70:516-9. 2011
    ..To determine coverage and generalisability of data in the Swedish Biologics Register ARTIS...
  8. doi request reprint How large are the productivity losses in contemporary patients with RA, and how soon in relation to diagnosis do they develop?
    Martin Neovius
    Clinical Epidemiology Unit T2, Department of Medicine Solna, Karolinska Institutet, SE 171 76 Stockholm, Sweden
    Ann Rheum Dis 70:1010-5. 2011
    ..To estimate the sick leave and disability pension trajectory in patients diagnosed with early rheumatoid arthritis (RA) 1999-2007, and in prevalent patients in 2007...
  9. ncbi request reprint Rheumatoid arthritis in Sweden. Drug prescriptions, costs, and adverse drug reactions
    P Blomqvist
    Karolinska Institutet, Department of Medical Epidemiology, Stockholm, Sweden
    J Rheumatol 27:1171-7. 2000
    ..We studied drug exposure, drug costs, and adverse drug reactions in patients with RA in Sweden from 1987 to 1997...
  10. doi request reprint Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden
    Martin Neovius
    Clinical Epidemiology Unit T2, Department of Medicine Solna, Karolinska Institutet, SE 171 76 Stockholm, Sweden
    Ann Rheum Dis 70:624-9. 2011
    ..To provide Swedish nationwide data on the prevalence of rheumatoid arthritis (RA), including variations by age, sex, geography, demography and education level, and assess antirheumatic treatment penetration...
  11. doi request reprint Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009
    M Neovius
    Department of Medicine, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm
    Scand J Rheumatol 40:8-15. 2011
    ..To measure small-area variations in sales per capita of tumour necrosis factor (TNF) inhibitors...
  12. pmc Swedish registers to examine drug safety and clinical issues in RA
    J Askling
    Clinical Epidemiology Unit, Department of Medicine, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden
    Ann Rheum Dis 65:707-12. 2006
    ..The approach described is a possible prototype for long term surveillance systems needed for the safe introduction of new treatments...
  13. pmc Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists
    J Askling
    Clinical Epidemiology Unit, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden
    Ann Rheum Dis 64:1421-6. 2005
    ..Existing studies of solid cancers in rheumatoid arthritis (RA) reflect cancer morbidity up until the early 1990s in prevalent cohorts admitted to hospital during the 1980s...
  14. pmc Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study
    J Askling
    Department of Medicine, Clinical Epidemiology Unit M9 01, Karolinska University Hospital Solna, SE 171 77, Stockholm, Sweden
    Ann Rheum Dis 65:1184-7. 2006
    ..Besides inflammation-lymphoma aetiology, information on risk of lymphoma in ankylosing spondylitis is particularly important as a benchmark in the evaluation of, for example, tumour necrosis factor inhibitors...
  15. ncbi request reprint Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden
    K Hellgren
    Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden
    Arthritis Rheumatol 66:1282-90. 2014
    ..This study was undertaken to assess the risk of lymphoma in AS and PsA overall and in relation to therapies, including tumor necrosis factor inhibitor (TNFi), for which lymphoma risks are a concern...
  16. ncbi request reprint A 10-year survey of inflammatory bowel diseases-drug therapy, costs and adverse reactions
    P Blomqvist
    Department of Medical Epidemiology, Karolinska Institutet, Stockholm, Sweden
    Aliment Pharmacol Ther 15:475-81. 2001
    ..Drug therapy for Crohn's disease and ulcerative colitis is based on anti-inflammatory and immunodulating drugs, nutritional support and surgical resection. Recently, new drugs have been introduced...